

| | | | |
|----------------------|--|---------------------------|------------|
| Department: | Pharmacy Management | Original Approval: | 10/26/2006 |
| Policy No: | PM557 | Last Approval: | 02/21/2024 |
| Policy Title: | Fraud, Waste, and Abuse Program Policy | | |
| Approved By: | Clinical Services Leadership Team | | |
| Dependencies: | CO289 – Fraud, Waste and Abuse Policy | | |

Purpose

This policy describes Community Health Plan of Washington’s (CHPW’s) fraud, waste, and abuse (FWA) program for Medicare Part D.

Policy

It is CHPW’s policy to comply with all applicable statutory, regulatory, and other Part D program requirements related to the delivery of the Medicare Part- D benefits and to ensure its pharmacy benefit manager (PBM) is in compliance with all applicable laws, rules, and regulations with respect to any Part D delegated activities. CHPW is committed to detect, prevent, and control fraud, waste and abuse among pharmacies, prescribers and members.

Definitions

Fraud

1. A deception or misrepresentation by a provider, beneficiary, sponsor, or any person acting on behalf of a provider, sponsor, or beneficiary with the knowledge (or who had reason to know or should have known) that the deception or misrepresentation could result in some unauthorized Part-D benefit to self or some other person, or some unauthorized Part-D payments; or
2. A claim that is false or fictitious, or includes or is supported by any written statement which asserts a material fact which is false or fictitious, or includes or is supported by any written statement that:

Omits a material fact; and

Is false or fictitious as a result of such omission; and

Is a statement in which the person making, presenting, or submitting such statement has a duty to include such material fact. It is presumed that, if a deception or misrepresentation is established and a Part-D claim is filed, the person responsible for the claim had the requisite

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

knowledge. This presumption is rebuttable only by substantial evidence. It is further presumed that the provider of the services is responsible for the actions of all individuals who file a claim on behalf of the provider (for example, billing clerks); this presumption may only be rebutted by clear and convincing evidence; or

3. Any act that constitutes fraud under applicable Federal or State Law.

Waste

1. The extravagant careless or needless expenditure of Government funds or the consumption of Government property that results from deficient practices, systems, controls, or decisions. The term “waste” also includes improper practices not involving prosecutable fraud.

Abuse

1. Any practice that is inconsistent with accepted sound fiscal, business, or professional practice which results in a claim, unnecessary costs, or payment for services or supplies that:
 - A. Are not within the concepts of medically necessary and appropriate care as defined by CMS or

Fail to meet professionally recognized standards for health care providers.

2. The term “abuse” includes deception or misrepresentation by a provider, or any person or entity acting on behalf of a provider in relation to a Part-D claim. A pattern of inappropriate practice will normally be required to find that abuse has occurred unless a specific action is deemed gross and flagrant.

Process

CHPW’s pharmacy benefit manager (PBM) complies with CMS’s FWA training requirements as stated in the PBM’s Fraud, Waste, and Abuse Training.

CHPW partners with its PBM in implementing the FWA program for Part D. Table 1 lists the activities of the FWA program.

Table 1: FWA Program Activities and Ownership

| Activities | Performed by CHPW | Performed by PBM |
|--|-------------------|------------------|
| Detection of pharmacies, prescribers (physicians, dentists, physician assistants, and nurse practitioners), and members with an unusual or excessive utilization pattern via data mining | X | X |
| Appropriate corrective actions against pharmacies related to over-or under-payment | | X |

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

| | | |
|---|---|---|
| Denial of claims for prescriptions written by Excluded Providers on the Health and Human Services (HHS) Office of Inspector General/General Services Administration lists | | X |
| Notify members regarding denial of payment for prescriptions written by Excluded Providers on the Health and Human Services (HHS) Office of Inspector General/General Services Administration lists | X | |
| Review of quarterly reports that include pharmacy audit results | X | |
| Analyze data that identifies prescribers and members with an unusual or excessive utilization pattern | X | |
| Investigate prescribers and members with unusual or excessive utilization patterns via review of medication profiles | X | |

Detection

The PBM uses four methods to audit and subsequently detect pharmacies with an unusual or excessive utilization pattern.

1. Continuous Automated Review

- Adjudicated claims from previous days are reviewed for a multitude of dispensing indicators, including average claim amounts, quantity vs. days' supply submission, generic/brand fill rates, proper use of DAW codes, and other variables.
- To identify and rank pharmacies based on dispensing indicators for initial fill and recurring refills.
- Conduct review of pharmacies based on this initial analysis.
- Results are logged and reviewed for problem trends and potential escalation treatment.
- Claims are reviewed and corrected prior to pharmacy payment and plan sponsor billing.

2. Desk Audits

When unusual patterns are identified at a particular pharmacy, the auditors:

- Compile a list of possible suspect claims.
- Request the supporting documentation for suspect claims from the pharmacy.
 - Supporting documentation include the front and back copy of the original prescription and copies of signature logs signed by beneficiaries.

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

Pharmacies may be selected for a desk audit by referral from other ESI departments or plan sponsor requests.

If the audit results in financial recovery, the amount is returned to CHPW.

3. Field Audits

The on-site audit process includes a detailed review of claims and quality assurance documentation performed on-site at the network pharmacy location. Network pharmacies are identified for field audits via

- Risk Assessment Protocol programs,
- Referrals (tips),
- Data previously reviewed deemed unreliable, and
- Next Day Desk/Phone Audits or a Historical Desk/Phone Audits indicate a pattern of errors, necessitating a review of a large amount of prescription documentation.

The audit includes verification that pharmacies are posting or distributing the “Medicare Prescription Drug Coverage and Your Rights” Pharmacy Notice (CMS-10147).

4. Investigative Audits

In this type of audit, the auditors go directly to the source of the necessary documentation rather than auditing the pharmacy. The scope includes, but is not limited to, the following:

- Inventory purchase verification,
- Physician and member audits,
- Review of medication destruction records, and
- Pharmacy trending analysis.

Member and Prescriber Analysis

The PBM uses its data mining programs; fraud, waste, and abuse detection software; and special reports to allow a qualified reviewer to determine whether the member’s drug usage patterns are appropriate for their recorded diagnoses and prescribed therapies. Physicians whose prescribing patterns present an appearance of possible fraud, waste, or abuse are identified in the same way.

CHPW’s Pharmacy department analyzes the reports and responds accordingly:

- If members are suspected of prescription diversion or physician shopping for narcotics, the members’ prescribers are contacted to notify them of potentially fraudulent activity.
- Medication claims of identified prescribers are reviewed to determine if fraudulent activities, such as script milling, have been perpetrated.

- When fraudulent activity is substantiated, the CHPW Pharmacy department will initiate appropriate corrective action and institute systematic changes to prevent similar violations from occurring. If it is determined that a violation of the Medicare Part D program has occurred, the CHPW Pharmacy department will notify its Compliance Officer and FWA Program Manager who takes appropriate actions including, but not limited to, notifying the Medicare Drug Integrity Contractors (MEDICs) Health Integrity (HI) for fraud, waste, and abuse issues and MEDIC SafeGuard Services (SGS) for compliance and enforcement activities within 60 days of detecting the violation.

Overpayment and Underpayment

When there is an over- or underpayment identified via various audit methods described above, PBM will work directly with affected pharmacies to initiate claim reversal and reprocessing. Claim reversal and reprocessing details will be found within the claim detail on the first billing cycle of each month.

PBM Oversight

The following are performed by the CHPW Pharmacy department:

- Review and analyze the quarterly reports produced by the PBM.
- Review the PBM’s FWA program annually to ensure full compliance with Part D requirements including, but not limited to, training and education related to FWA
- Annual monitoring to ensure that claims are denied for prescriptions written by HHS Excluded Providers.
- CHPW complies with law enforcement, CMS, and CMS’ designee requests to monitor providers within their network that CMS has viewed as potentially abusive or fraudulent.
- In the event that the PBM or its employees violates the application rules regarding OIG/GSA checks, CHPW may take immediate corrective action

Review and analyze the quarterly reports produced by CMS. Any findings by the clinical pharmacists will be distributed to the CHPW Compliance department.

List of Appendices

- A. Detailed Revision History

Citations & References

| | |
|------------|--|
| CFR | 42 CFR § 423.504(B)(4)(VI)(G); 42 CFR § 438.608(A)(1)(VII) |
|------------|--|

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

| | | |
|------------------------------------|---|--|
| WAC | | |
| RCW | | |
| LOB & Contract Citation | <input type="checkbox"/> WAHIMC | |
| | <input type="checkbox"/> BHSO | |
| | <input type="checkbox"/> Wraparound | |
| | <input type="checkbox"/> SMAC | |
| | <input type="checkbox"/> HH | |
| | <input type="checkbox"/> AHE | |
| | <input checked="" type="checkbox"/> MA/DSNP | Prescription Drug Benefit Manual Chapter 9 |
| <input type="checkbox"/> CS | | |
| Other Requirements | | |
| NCQA Elements | CR 5; MA 18 | |

Revision History

| | |
|--------------------|--|
| SME Review: | 10/26/2006; 11/13/2007; 07/01/2008; 01/13/2009; 08/05/2009; 09/11/2009; 04/21/2010; 03/28/2011; 04/19/2011; 03/26/2012; 02/21/2013; 03/24/2014; 04/13/2015; 03/15/2016; 03/01/2017; 03/02/2018; 03/12/2019; 02/27/2020; 02/22/2021; 02/02/2022; 01/31/2023; 02/19/2024 |
| Approval: | 09/09/2009; 04/30/2010; 05/25/2011; 04/04/2012; 04/19/2013; 04/23/2014; 03/18/2016; 03/14/2017; 03/13/2018; 03/13/2019; 03/06/2020; 03/02/2021; 02/28/2022; 02/13/2023; 02/21/2024 |

Appendix A: Detailed Revision History

| Revision Date | Revision Description | Revision Made By |
|---------------|--|-------------------|
| 10/26/2006 | Original | Pharmacy Mgmt |
| 11/13/2007 | Minor formatting changes | Eric Guyette |
| 07/01/2008 | Minor formatting changes | Rachel Koh |
| 01/13/2009 | Review for style and formatting | Sunny Otake |
| 08/05/2009 | Content Update | Jennifer Mui |
| 09/09/2009 | Approval | MMLT |
| 09/11/2009 | Review for style and formatting | Jennifer Carlisle |
| 04/21/2010 | Content Update | Maria Chan |
| 04/30/2010 | Approval | MMLT |
| 03/28/2011 | Content Update | Rachel Koh |
| 04/19/2011 | Content Update | Maria Chan |
| 05/25/2011 | Approval | MMLT |
| 03/26/2012 | Review and no change | Maria Chan |
| 04/04/2012 | Approval | MMLT |
| 02/21/2013 | Content update | Maria Chan |
| 04/19/2013 | Approval | MMLT |
| 03/24/2014 | Review with minor changes | Annie Lam |
| 04/23/2014 | Approval | MMLT |
| 04/13/2015 | Changes, and formatting changes | Nonye Connor |
| 04/23/2015 | Approval | MMLT |
| 03/15/2016 | Review and no changes | Mary Eckhart |
| 03/18/2016 | Approval | MMLT |
| 03/01/2017 | Moved to new template. Minor content update. | Mary Eckhart |
| 03/14/2017 | Approval | MMLT |
| 03/02/2018 | Moved to new template. | Mary Eckhart |
| 03/13/2018 | Approval | MMLT |
| 03/12/2019 | Reviewed, no changes | Dustin Peskuric |
| 03/13/2019 | Approval | MMLT |
| 02/27/2020 | Updated Citations Table | Dustin Peskuric |
| 02/27/2020 | Reviewed, minimal changes. | Ivan Figueira |
| 02/28/2020 | Reviewed and approved | Omar Daoud |
| 03/02/2020 | Department Approval | Yusuf Rashid |
| 03/06/2020 | Approval | CMO Cabinet |
| 02/22/2021 | Reviewed. No Changes | Omar Daoud |

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

| | | |
|------------|--|-----------------------------------|
| 03/01/2021 | Approval | Yusuf Rashid |
| 03/02/2021 | Approval | CMO Cabinet |
| 02/02/2022 | Reviewed with no changes, Department approval. | Omar Daoud |
| 02/28/2022 | Approval | CMO Cabinet |
| 01/31/2023 | Reviewed, no changes | Omar Daoud |
| 02/13/2023 | Approval | Clinical Service Leadership Team |
| 02/19/2024 | Reviewed, no changes | Omar Daoud |
| 02/21/2024 | Approval | Clinical Services Leadership Team |